CISPLATIN VERSUS CISPLATIN PLUS D-TRP-6-LHRH IN THE TREATMENT OF OVARIAN-CANCER - A PILOT TRIAL TO INVESTIGATE THE EFFECT OF THE ADDITION OF A GNRH ANALOG TO CISPLATIN

Thirty-four patients with histologically confirmed ovarian cancer were entered into a pilot study. Patients were randomized to receive cispl atin alone or cisplatin plus D-Trp-6-LHRH (decapeptyl). Objective resp onse (complete and partial response) was documented in 9 of 14 patient s on cisplatin and in 12 of 18 patients on cisplatin plus decapeptyl. Median time to treatment failure and median survival times were the sa me in the two treatment regimens. Toxicities were similar in the two t reatment arms, except for hot flashes which only occurred in patients on cisplatin plus decapeptyl.